Santi is a serial entrepreneur and investor in analytical chemistry, technology- and technology-based start-ups. After graduating in Business Studies, Santi has held general management, sales management, R&D and business development roles over the past 25 years. He co-founded and managed Mestrelab Research SL from a two-person bootstrap start-up to a valuation in excess of €20Mn, and has made a partial strategic exit from this venture. Santi was a Board member of eMolecules Inc. between 2008 and 2018, where he oversaw growth of the e-commerce platform from an angel-funded start-up to revenues of mid 8 figures in 2019. Santi co-founded Imspex Diagnostics Ltd in 2011 and continues to run the company. He has led three successful funding rounds and has made a partial exit from the company.
Santi speaks fluent Spanish, English and Galician, as well as French. He has significant expertise in international commerce, e-commerce, analytical chemistry, software R&D project management, hardware development and manufacturing, general management and M&As.
John has over three decades’ experience of board-level executive and NED chairman roles in private and publicly listed companies, government departments including public private industry partnerships in the UK and overseas. He has specialist expertise in diagnostic technologies, instruments and devices, particularly in highly infectious respiratory human and animal diseases, with a deep knowledge of translational population genomics and personalised medicine. John transitioned from a foundation career in corporate, commercial and licensing legal practice, the London insurance industry and ESG technologies to executive roles in global Life Science, biotechnology and environmental sector companies. Seasoned in engaging executives, shareholders and stakeholders at all levels of seniority, he articulates visions for business improvement and ESG aligning disparate parties towards common purposes and goals. As a result, he has launched and led a variety of companies from start-up to become publicly listed entities with robust ESG governance and expansive global commercial footprints. John’s insights into global healthcare policies, practical translational expertise and senior legal background will help guide Impex’s mission to become the global leader in next-generation breath diagnostics.
As a corporate finance specialist, Robin brings more than 30 years of experience of fundraising, managing the sale of businesses and acting in an advisory capacity to VC/PE backed early-stage, tech-centric, disruptive and knowledge-rich start-ups, established businesses looking to grow and business in turn-around scenarios. He is well-acquainted with the financial, strategic and operational activities across the pharmaceutical, medical device, healthcare, therapeutics development, electronics, digital communications and finance/ investment management industries.
Dr Michael Graz
Michael has 25 years of commercial, research and development and teaching experience in the Life Sciences. This includes ten years in the diagnostics, medical device and biotechnology sectors where he has held multiple C-suite positions to start up, lead, support or turn around SMEs and mid-sized multinational corporations in the UK, USA, South Africa, South America and Asia.
His clients have ranged from privately owned companies through to governmental and intergovernmental organisations and he has a network of international contacts that reflects this breadth of industry experience.
Michael has lived on four different continents and speaks English, German and Spanish fluently. He is skilled at identifying potential commercial opportunities and in being able to realise these by strong strategic thinking, astute people management, familiarity with operational practices and well-established knowledge of financial management. He has raised $15Mn in pre-Series A funding and in excess of $3Mn in grant funding to date and has seven patent families to his name in microbial control and diagnostics.
Michael has PhDs in Anatomy and in Pharmaceutical chemistry and has co-authored 30 peer-reviewed papers related to microbial control, antimicrobial therapeutics and alternative approaches to managing antimicrobial resistance.
Thomas has more than 20 years of experience in developing analytical solutions using gas chromatography-ion mobility spectrometry technology in industrial-, food-, cosmetic- and healthcare applications
Dr Stewart Clark
Stewart has 15 years of research and manufacturing experience in Quality and Regulatory roles in the pharmaceutical, biotechnology and medical technology sectors. He is recognised as a Quality Risk Management expert and has lead R&D teams in achieving and maintaining certification across the ISO family of quality- and risk management systems. Stewart is conversant with GxP Regulatory environments and has assisted SMEs when working with the FDA, EMA and MHRA for the past five years.
He has a PhD in Microbiology from the Center for Biofilm Engineering at Montana State University and is an active member of both IOSH and ISTR.